Becton, Dickinson and Company (BDX) Upgraded to Strong-Buy by BidaskClub

BidaskClub upgraded shares of Becton, Dickinson and Company (NYSE:BDX) from a buy rating to a strong-buy rating in a research report sent to investors on Tuesday, July 11th.

A number of other research firms have also commented on BDX. Zacks Investment Research lowered Becton, Dickinson and from a buy rating to a hold rating in a research report on Thursday, May 4th. Raymond James Financial, Inc. raised Becton, Dickinson and from an outperform rating to a strong-buy rating and decreased their target price for the company from $210.00 to $180.00 in a research report on Friday, June 30th. Evercore ISI raised Becton, Dickinson and from an in-line rating to an outperform rating and raised their target price for the company from $186.00 to $200.00 in a research report on Monday, April 24th. Cowen and Company reaffirmed an outperform rating and set a $230.00 target price (up from $200.00) on shares of Becton, Dickinson and in a research report on Monday, July 10th. Finally, Jefferies Group LLC reaffirmed a buy rating and set a $200.00 target price on shares of Becton, Dickinson and in a research report on Wednesday, March 29th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $195.79.

Becton, Dickinson and (BDX) traded up 1.08% during mid-day trading on Tuesday, hitting $200.36. 1,251,199 shares of the company traded hands. The company’s 50-day moving average is $198.90 and its 200-day moving average is $187.70. The stock has a market capitalization of $45.59 billion, a price-to-earnings ratio of 58.02 and a beta of 1.05. Becton, Dickinson and has a one year low of $161.29 and a one year high of $206.63.

Becton, Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping analysts’ consensus estimates of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The company had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.06 billion. During the same period in the prior year, the firm earned $2.35 earnings per share. Becton, Dickinson and’s revenue for the quarter was down 5.1% on a year-over-year basis. Analysts predict that Becton, Dickinson and will post $9.46 EPS for the current year.

WARNING: This story was published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.com-unik.info/2017/08/12/becton-dickinson-and-company-bdx-upgraded-to-strong-buy-at-bidaskclub-updated-updated-updated.html.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be paid a $0.73 dividend. The ex-dividend date is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.46%. Becton, Dickinson and’s dividend payout ratio (DPR) is currently 83.43%.

In other news, insider Ellen R. Strahlman sold 9,283 shares of Becton, Dickinson and stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $198.21, for a total value of $1,839,983.43. Following the sale, the insider now directly owns 26,638 shares in the company, valued at approximately $5,279,917.98. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Jeffrey S. Sherman sold 28,765 shares of Becton, Dickinson and stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $185.98, for a total value of $5,349,714.70. Following the sale, the vice president now owns 70,821 shares in the company, valued at $13,171,289.58. The disclosure for this sale can be found here. Insiders sold a total of 44,019 shares of company stock worth $8,368,433 over the last ninety days. Insiders own 1.40% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Guardian Life Insurance Co. of America raised its stake in Becton, Dickinson and by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock valued at $150,000 after buying an additional 6 shares in the last quarter. Family Firm Inc. increased its stake in Becton, Dickinson and by 0.5% in the second quarter. Family Firm Inc. now owns 1,212 shares of the medical instruments supplier’s stock valued at $236,000 after buying an additional 6 shares during the period. Northwest Quadrant Wealth Management LLC increased its stake in Becton, Dickinson and by 0.4% in the second quarter. Northwest Quadrant Wealth Management LLC now owns 1,686 shares of the medical instruments supplier’s stock valued at $332,000 after buying an additional 6 shares during the period. Wellington Shields & Co. LLC increased its stake in Becton, Dickinson and by 0.3% in the second quarter. Wellington Shields & Co. LLC now owns 2,541 shares of the medical instruments supplier’s stock valued at $496,000 after buying an additional 7 shares during the period. Finally, Parkside Financial Bank & Trust increased its stake in Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after buying an additional 9 shares during the period. Institutional investors own 75.71% of the company’s stock.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

What are top analysts saying about Becton Dickinson and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Becton Dickinson and Company and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit